% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • sand_snow sand_snow Jan 23, 2014 12:57 PM Flag

    Altogether, these results support evidence that IL-33 acts asa potent adjuvant capable ofinducing and modulating potent Ag-specific cell-mediated immunity in a variety of pathogens.

    Together, these results indicate that the increase in the frequency and
    phenotype of the IL-33-adjuvanted vaccine-induced Ag-specific P14 CD8
    T cells after a prime
    and boost vaccination may be a prediction of the protective correlates ofimmunity behind the
    therapeutic efficacy of immunoadjuvant IL-33 against the established TC-1 tumors (Fig. 6B). We
    are currently investigating the ability of IL-33 to generate central memory immunity, since
    central memory T cells are important subsets of memory CD8
    T cells that also mediate optimal
    protective immunity against pathogens (47,48). Overall, understanding the mechanism of action
    by which IL-33 influences the expansion and development of heterogeneous CD8
    T cell
    populations in vaccines is an important area for further investigation.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
10.57-0.31(-2.85%)10:54 AMEDT